54
Participants
Start Date
January 26, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
CTM
decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act.
Celestone
standard of care
Indiana Hand to Shoulder Center, Indianapolis
Collaborators (1)
CTM Biomedical
INDUSTRY
Indiana Hand to Shoulder Center
OTHER